OR25-08 Brain-Derived Neurotrophic Factor levels (BDNF) in Hyponatremia Correction -Subanalysis of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial
Abstract
Abstract Disclosure: J. Beck: None. E. Kustos-Toth: None. L. Seeger: None. S. Monnerat: None. C. Bathelt: None. J. Refardt: None. M. Christ-Crain: None. Background: Hyponatremia is the most common electrolyte disorder in clinical practice and is associated with cognitive impairment. We have recently shown that correction of sodium levels can improve cognitive function1. Growing evidence suggests that serum brain-derived neurotrophic factor (BDNF) correlates with cognitive performance, playing a crucial role in learning, memory, and development of neurocognitive diseases, like dementia and depression. There is currently no data on serum BDNF levels in the context of hyponatremia. Aim: The primary objective of this study was to investigate the effect of hyponatremia correction on serum BDNF levels. Design and MethodsSecondary analysis of a prospective randomized, double-blind, crossover, placebo-controlled trial of 4-week empagliflozin 25mg/d vs placebo treatment in patients with syndrome of inappropriate antidiuresis (SIAD), conducted at the University Hospital Basel, Switzerland, from December 2017 to August 2021. Serum BDNF levels were assessed by quantitative enzyme-linked immunosorbent assay (ELISA). Statistical analyses were performed using R version 4.4.2. Results: A total of fourteen patients were included in the analysis (50% female, median age 72 years [65-77]. At baseline, the median sodium in the empagliflozin group was 131 mmol/l [128-132], which increased to 134…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.